
Senate Bill Would Fine Pharmacists $1000 a Day for Refusing to Furnish Plan B
Pharmacists could soon face hefty fines for refusing to provide Plan B to women who request it.
Pharmacists could soon face hefty fines for refusing to provide Plan B to women who request it.
The “Access to Birth Control Act” (S. 2960) recently introduced in the US Senate by New Jersey Senator Cory Booker would require pharmacists to provide “any drug or device approved by the [FDA] to prevent pregnancy…without delay.” The bill explicitly states that emergency contraception would be included under the purview of the law.
Under the proposed legislation, pharmacists refusing to dispense emergency contraception would be fined $1000 per day until the prescription is filled, or up to $100,000 “for all violations adjudicated in a single proceeding.”
“Reports of pharmacists refusing to fill prescriptions for contraceptives, including emergency contraceptives, have surfaced in states across the nation,” the text of the bill reads. “Since emergency contraception
Interestingly, states like
Meanwhile, a first-of-its-kind law recently passed in
Virginia Senator Tim Kaine, co-sponsor of S. 2690, says the initiative will offer access to women who want to prevent unplanned pregnancies.
“Access to contraception is a protected right for women,” he told Gray DC. “…Your access shouldn’t depend on the zip code you live in or the state you live in.”
Sen. Kaine stopped short of saying pharmacists shouldn’t be able to hold personal beliefs; he just doesn’t believe pharmacists should be able to let personal convictions interfere with their work.
“A pharmacist is free in their own life to live the way they want, but pharmacists should not, as a medical professional, block women from getting prescriptions,” he asserted.
A number of pharmacists in Washington State are currently fighting
S. 2960 has been assigned to the Senate Health, Education, Labor, and Pensions Committee.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.